To evaluate plan quality of a novel MRI-compatible direction modulated brachytherapy (DMBT) tandem applicator using 192 Ir, 60 Co, and 169 Yb HDR brachytherapy sources, for various cervical cancer high-risk clinical target volumes (CTV HR ). Materials and Methods: The novel DMBT tandem applicator has six peripheral grooves of 1.3-mm diameter along a 5.4-mm thick nonmagnetic tungsten alloy rod. Monte Carlo (MC) simulations were used to benchmark the dosimetric parameters of the 192 Ir, 60 Co, and 169 Yb HDR sources in a water phantom against the literature data. 45 clinical cases that were treated using conventional tandemand-ring applicators with 192 Ir source ( 192 Ir-T&R) were selected consecutively from intErnational MRI-guided BRAchytherapy in CErvical cancer (EMBRACE) trial. Then, for each clinical case, 3D dose distribution of each source inside the DMBT and conventional applicators were calculated and imported onto an in-house developed inverse planning optimization code to generate optimal plans. All plans generated by the DMBT tandem-and-ring (DMBT T&R) from all three sources were compared to the respective 192 Ir-T&R plans. For consistency, all plans were normalized to the same CTV HR D90 achieved in clinical plans. The D 2 cm3 for organs at risk (OAR) such as bladder, rectum, and sigmoid, and D90, D98, D10, V100, and V200 for CTV HR were calculated. Results: In general, plan quality significantly improved when a conventional tandem (Con.T) is replaced with the DMBT tandem. The target coverage metrics were similar across 192 Ir-T&R and DMBT T&R plans with all three sources (P > 0.093). Yb source generally resulted in the greatest OAR sparing when the CTV HR were larger and irregular in shape, while for smaller and regularly shaped CTV HR (<30 cm 3 ), OAR sparing between the sources were comparable. Conclusions: The DMBT tandem provides a promising alternative to the Con.T design with significant improvement in the plan quality for various target volumes. The DMBT T&R plans generated with the three sources of varying energies generated superior plans compared to the conventional T&R applicators. Plans generated with the 169 Yb-DMBT T&R produced best results for larger and irregularly shaped CTV HR in terms of OAR sparing. Thus, this study suggests that the combination of the DMBT tandem applicator with varying energy sources can work synergistically to generate improved plans for cervical cancer brachytherapy. 
INTRODUCTION
External beam radiation therapy (EBRT) to the pelvis concurrently with (cisplatin based) chemotherapy, followed by intracavitary brachytherapy (ICBT) or interstitial brachytherapy as a boost to the gross disease, has become the standard of care in locally advanced cervical cancer (LACC) treatment. [1] [2] [3] [4] [5] Brachytherapy became the boost technique of choice due to its ability to deliver a highly local and conformal dose to the target volume while simultaneously achieving rapid dose falloff, thus minimizing damage to surrounding radiosensitive normal tissues (such as rectum, bladder, sigmoid, and bowel). Many studies demonstrated that cervical cancer treatment outcomes improved using various brachytherapy techniques. [6] [7] [8] [9] [10] [11] [12] In 2013 and 2014, Han et al. 7 and Gill et al., 8 analyzed 7359 and 7654 cervical cancer patients using the Surveillance, Epidemiology, and End Results (SEER) and National Cancer Database (NCDB) respectively. They reported that the overall survival rate has significantly increased when brachytherapy is included in the treatment, whether alone or in combination with EBRT, compared to EBRT alone.
Traditionally, ICBT treatment has been implemented by loading brachytherapy sources into intracavitary applicators using 2D radiographs based on dose to points (A/B), 1 irrespective of target size and shape, resulting in a standardized pear-shape isodose configuration. 6 A clear limitation of this technique is the absence of a 3D image of the applicators and surrounding anatomy, resulting in impossible assessment of over/under-dosage to the target volume and normal tissues. 1, [4] [5] [6] [7] Since about 2000, a new extensive clinical workflow 13 replacing 2D brachytherapy was developed through the gynecology Groupe Europ een de Curieth erapie and European SocieTy for Radiotherapy and Oncology (GEC-ESTRO) (I-IV) [14] [15] [16] [17] and the American Brachytherapy Society (ABS) (I-III) [18] [19] [20] recommendations. These reports recommend implementing 3D MRI and/or CT image-guided adaptive brachytherapy (IGABT) for evaluation of disease extension and dose adaptation. MRI provides the highest soft tissue contrast which is useful for tumor and organs at risk (OAR) delineations. The GEC-ESTRO reports [14] [15] [16] [17] introduced MRI as the gold standard for IGABT along with adaptive target concepts and 3D based adaptive dose-volume histogram (DVH) to provide adequate dose coverage of high-risk clinical target volume (CTV HR ) while sparing OARs, which in turn lead to significant improvement in clinical outcome. [10] [11] [12] 21 Local control at 3 yr with MR IGABT significantly improved:
21 95-100% in limited stages (IB-IIB), and 85-90% in advanced stages (IIB-IV), which indicated a relative reduction in pelvic recurrence of about 65-70% compared to historical results. Overall survival of 3D MR IGABT patients increased by 10% 11 and major morbidity decreased by 50% 22 compared to the traditional 2D based brachytherapy. The conceptual framework for cervical cancer treatment is nicely summarized in the recent ICRU/GEC-ESTRO report 89. 1 Based on these improvements in clinical outcomes, MR IGABT is fast becoming the worldwide standard for radiotherapy of LACC. Further improvement would require implementing new and innovative technologies in all aspects of the brachytherapy technology, including applicators.
With conventional intracavitary applicators, it is often times challenging to shape the isodose lines to spare the OARs and/or conform to CTV HR . This is largely due to the radially isotropic 6 dose distributions generated by commercial HDR brachytherapy sources that cannot be altered. For example, an irregularly shaped CTV HR would require high dose modulation from the applicators in order to minimize the dose to surrounding OARs especially in the anterior-posterior direction where rectum and bladder are typically seated. This can partially be achieved by using commercial metalshielded ovoids, 23, 24 or spacer balloons, 25 but they are generally limited to intensity modulation at the level of the vaginal cuff where they are seated. When the gross disease sits laterally and superiorly away from the ovoids, OAR sparing becomes more challenging as dosimetric coverage of the target volume may necessarily force spreading of dose to the normal tissues. Therefore, to deliver the prescription dose to bulky and irregular tumors, the ICBT combined with interstitial brachytherapy such as MUPIT, 4 Syed/Neblett, 4 Vienna, 26 and Utrecht 27 applicators were proposed in the past. Although the interstitial approach can provide more conformal dose coverage, especially with bulky LACC, 12 this technique is more invasive and plan quality depends on where the needles are placed and hence sensitive to physician skills in insertion. 3, 4 Other potentially promising technologies, based on the intensity modulated brachytherapy (IMBT) concept, 28 utilizes intelligently designed metal alloy shielding to create anisotropic dose profile(s) for use in ICBT and interstitial brachytherapy techniques. Examples include dynamic modulated brachytherapy, 29 rotating shield brachytherapy (RSBT), [30] [31] [32] and direction modulation brachytherapy (DMBT) [33] [34] [35] [36] applicators. With RSBT a miniature electronic brachytherapy x-ray source 37 or radionuclide 153Gd source 32 including independent layers of rotating shield can travel through an applicator and radiation dose can be modulated by controlling the time and angles of rotating shield layers. [30] [31] [32] The DMBT idea 29, [33] [34] [35] [36] is essentially based on the modulation of directional radiation dose distribution of an isotropic 192 Ir source created through fitting nonmagnetic tungsten alloy shield inside conventional applicators. This concept has been previously demonstrated to improve OAR sparing in breast, 29 rectum, 33, 34 and cervical cancer 35, 36 brachytherapy. The novel MR-compatible DMBT tandem applicator in particular 35, 36, 38, 39 has six channels placed equidistantly around the periphery of a 5.4-mm diameter tungsten alloy rod, capable of generating highly conformal dose distributions tailored to each individual patient anatomy that are delineated through MRI and CT images. For example, the DMBT tandem-and-ovoid (DMBT T&O) HDR plans generated over 15 cervical cancer cases improved the D 2 cm3 over conventional tandem-and-ovoid plans by 8.5% for bladder, 21.1% for rectum, and 40.6% for sigmoid. 35 Also, in a more recent study, 36 OAR D 2 cm3 were decreased up to 9.5% for bladder, 22.9% for rectum, and 9.8% for sigmoid, when conventional tandem-and-ring (T&R) were replaced with the DMBT tandemand-ring (DMBT T&R) plans. Moreover, the combination of the DMBT T&R with (Vienna applicator style) interstitial needles resulted in 2.8%, 5.6%, and 5.4% average dose reductions in bladder, rectum, and sigmoid, respectively, compared to the conventional T&R with interstitial needles. Presently, various high and middle energy HDR brachytherapy sources are available commercially and offer different clinical advantages. 40 Therefore, there is a unique opportunity to evaluate the synergy between the DMBT tandem in combination with various brachytherapy sources of different energies as varying degree of beam directionality can be achieved. The purpose of this study is to then evaluate plan quality improvements when three different HDR sources, namely Cobalt 60 ( Figure 1 shows the proposed DMBT-concept tandem applicator design. The applicator is MR-compatible 38 and has a total diameter of 6.0 mm. It consists of a 5.4-mm diameter tungsten alloy rod (95% W, 3.5% Ni, and 1.5% Cu, q = 18.0 g/cm 3 ) wrapped inside a 0.3-mm thick bio-safe thermoplastic sheath (q = 1. 
MATERIALS AND METHODS

2.A. DMBT tandem applicator
2.B. Patients
The first fraction plan of 45 consecutively-treated cervical cancer patients (FIGO IB-IVB), using pulsed dose rate (PDR) brachytherapy, enrolled in the intErnational MRIguided BRAchytherapy in CErvical cancer (EMBRACE) registry trial, treated at the Aarhus University Hospital, Aarhus, Denmark, were used in this study. 41 All plans had T2-weighted MRI where all OARs and CTV HR were subsequently delineated. Plans were optimized on the BrachyVision TM treatment planning system based on the GEC-ESTRO guidelines. The mean (range) of CTV HR volumes was 34 AE 19.79 cm 3 (9.0-93.3 cm 3 ) at the time of the first brachytherapy fraction. All patients received an EBRT course of 1.67 Gy 9 30, 2.0 Gy 9 25, or 1.80 Gy 9 25 fractions to the whole pelvis prior to brachytherapy. All brachytherapy treatments were carried out with conventional T&R applicators with/without interstitial needles where appropriate.
2.C. Brachytherapy sources and Monte Carlo simulations
The 192 Ir, Nucletron-microselectron HDR-version 2 (mHDR-V2), 40,42 60 Co (Co0.A86), Eckert&Ziegler BEBIG Corporation, 40, 43 and 169 Yb (4140), Implant-Sciences-Corporation, 40, 44 brachytherapy sources were used for dose calculation inside the conventional and DMBT tandem applicators using Monte Carlo (MC) simulations. The total Yb source, respectively. MC radiation transport calculations are performed using MCNP code version 2.6. 45 The MC cross-sections used in these simulations were based on ENDF/B-VI.8 libraries.
As recommended, 41, 43 the NuDat spectrum database was used for source simulations. All recommendations of AAPM TG43, 46 and TG229 reports 40 for high energy brachytherapy dosimetry were considered for source simulations. First; MC TG43 radial dose function, g L (r), and 2D anisotropy function, F(r, h), were evaluated in water phantom to establish the source benchmark accuracy. More details about TG43 source benchmark against the literature are provided elsewhere. 47 Second; the calibrated sources were positioned in the center of the Con.T and one groove of DMBT tandem to calculate the 3D dose matrices to water from À10 to 10 cm along the three Cartesian axes. To minimize the impact of voxel size effect and volume averaging 46 in dosimetry, voxel sizes of 1-mm 3 and 2.5-mm 3 were used for radial distances of r < 5-cm and 5-cm< r <10-cm, respectively, and then subsequently interpolated into a 1-mm 3 resolution. The photon cutoff was selected to be 10 keV. 40 Simulations were performed with 10 9 number of photon histories for each case to achieve a statistical uncertainty of <0.5%, and <1.6% for source benchmark and tandem applicators in most of regions respectively.
2.D. Plan optimization
All 45 cases were replanned with the conventional T&R and DMBT T&R applicators, normalized to the same D90 achieved in the clinical plans, while the OAR D 2 cm3 limits were respected based on the GEC-ESTRO guidelines. [14] [15] [16] [17] In addition, those plans that had interstitial needles were replanned without use of needles (i.e., strictly limiting to intracavitary brachytherapy planning) to limit confounding variables as the focus was on the impact the various source energies make when combined with the DMBT tandem, for varying CTV HR volumes. The source strengths were set to a constant 1 Ci for each of the three sources. In total, 135 individual plans (=3 sources 9 45 planning cases) with the DMBT T&R and 45 individual "reference" plans (=1 192 Irsource 9 45 planning cases) with the conventional T&R applicators were generated using an in-house developed inverse optimization code based on gradient projection convex optimization algorithm. 35, 36 More details about the optimization algorithm are provided elsewhere. 33, 35 The dwell positions used in clinical plans were fixed while the dwell times were considered the decision variables to be optimized. Several constraints were applied during the optimization, including the CTV HR /OAR dose limits, and non-negativity of dwell times. 35 Individual dwell times were set to not exceed 800 s inside tandem while total dwell times to not exceed 3000 s inside the ring per clinical protocol. This is to ensure close emulation of the planning practice in clinic, as well as to preserve the original pear-shaped dose distribution. During optimization, all variables were kept constant for all plans and no manual intervention thereafter. This is done to avoid introducing bias. All clinically relevant DVH parameters such as D98, D90, D10, V100, and V200 for CTV HR and D 2 cm3 for OARs were recorded. The optimized plans with the 192 Ir-T&R combination were considered the "reference" plans to which all other DMBT plans was compared. Figs. 2(a), 2(b) ]. The differences between g L (r) and benchmark data were less than 1.5%, 1.6%, and 1.8% for 192 Ir, 40 60 Co, 43 and 169 Yb 44 respectively. These values for F (2 cm h) were less than 1.9%, 2.1%, and 2.2% for 192 Ir, 60 Co, and 169 Yb respectively. The g L (r) combined uncertainties were <1.2% for distances <2 cm and <2% for distances from 2 to 10 cm for all sources. F(r, h) showed deviation <1.1% for angles 10°≤ h < 170°. This deviation ranged from 0.2 to 2.2% for angles close to longitudinal source (0°< h < 10°or 170°< h < 180°) which agree with the 5% uncertainties that is reported by TG229. 40 As shown in Fig. 2(c) Co sources, and the difference increased for larger distances (>3 cm). The normalized dose for DMBT tandem are similar between sources, and are smaller than those with Con.T for larger distances (>1 cm). These values for close distances (<1 cm) to DMBT tandem are higher than Con.T, due largely to the normalization distance where the gradient is relevant.
RESULTS
3.A. Monte Carlo simulations
Normalized transverse 2D anisotropy for conventional and DMBT tandem at (1 cm, 0°) is shown in Fig. 2(d) . Transverse anisotropy for Con.T is the unit normal. DMBT shield generated less back spill radiation for all three sources than Con.T. 169 Yb provides the least back spill radiation (~180°) compared to the other sources. For instance, at 1 cm, the backside leakage radiation (180°) reduced to 16.5% for 192 Ir, 37.5% for 60 Co, and 2.44% for 169 Yb. Co source, on the other hand, provides the least directional beam, which makes sense as the average energy is >13 times than that of the 169 Yb source.
3.B. Treatment planning data
Quantitative planning results of CTV HR and OARs DVH parameters for the 192 Ir, 60 Co, and 169 Yb sources used in combination with the DMBT T&R and the reference 192 Ir-T&R applicators are listed in Table I . In terms of target coverage (D90, D98, V100), no significant differences were observed between the DMBT T&R and T&R plans (P > 0.059). In terms of target hotspots (D10), significant differences were observed for 60 Co (P < 0.001) and 192 Ir (P = 0.035) sources, while these values for the 169 Yb source was insignificant (P = 0.126). Moreover, 60 Co had the greatest V200 values while the smallest values were for the 169 Yb source. This means that the 60 Co-DMBT T&R combination generates greater hot spots and has less dose conformality than the respective 192 Ir and 169 Yb plans. The mean D 2 cm3 values for the DMBT T&R plans with all three sources were significantly less than the reference 192 Ir-T&R plans (Table I ). The 169 Yb-DMBT T&R plans, in particular, had the greatest improvements in terms of D 2 cm3 sparing for all three OARs. Also, the 192 Ir-DMBT T&R plans did better than the 60 Co-DMBT T&R plans in general for larger CTV HR volumes. The greatest D 2 cm3 individual reductions achieved amongst the 45 cases with the 192 Ir-DMBT T&R were À45.3%, À26.5%, and À18.3% for the bladder, rectum, and sigmoid respectively. These corresponding values were À33%, À12.9%, and À12.9% for the 60 Co-DMBT T&R and À49.9%, À39.2%, and À23.1% for the 169 Yb-DMBT T&R plans. First of all, it can be observed that the D 2 cm3 reduction increases with the increasing CTV HR volume, and the vast majority of data points are on the negative side indicating the general plan quality improvement achieved with the DMBT applicator for vast majority of cases (i.e., the linear regression lines are all below zero and have negative slopes). Specifically, 89% (40/45), 87% (39/45), and 97% (44/45) of the cases had lower D 2 cm3 achieved by the 60 Co-DMBT T&R plans for the bladder, rectum, and sigmoid compared with the reference 192 Ir-T&R plans respectively. These values were 169 Yb-DMBT T&R plans. For those cases that the DMBT plans could not improve (8/45), the average D 2 cm3 increase was <1.6% beyond that of the reference plans. Also, in all of such cases, only one of the three OAR doses had failed to improve, i.e., no case had two or more OARs with worse sparing than the reference plans. Another important observation to note is the linear regression lines showed the 169 Yb-DMBT plans with the greatest negative slope amongst the three sources along with the largest absolute D 2 cm3 sparing, especially for larger CTV HR volumes, indicating the need for greater dose modulation as the target volume becomes bigger and more irregular in shape.
With the highest degree of beam directionality achieved with the 169 Yb-DMBT (Fig. 3) , this source and the DMBT tandem combination enables the best capacity to create conformal dose distributions. This also means, as the target volume gets smaller and less irregular in shape, the need for dose modulation diminishes and the differences between the three sources also narrows, as observed. For example, for CTV HR volume of about ≤30 cm 3 , the quality of plans achieved amongst the three sources is similar [ Fig. 4(d) ]. Beyond that point, however, the need for dose modulation increases and the 169 Yb source noticeably does better job of achieving more conformal plans. This is followed by the 192 Ir and then the 60 Co source as intuitively expected per Fig. 3 .
DISCUSSION
The concept of IMBT, 28 achieved through directional beams, has now been successfully realized in a practical intrauterine tandem applicator design via utilization of intelligently designed tungsten alloy that fits inside the traditional dimensions of a tandem applicator 23, 35, 36 (Fig. 1 ). This novel tandem design was then combined with three sources covering broad range of practical brachytherapy energies (92.7 keV-1.25 MeV) 40 to evaluate treatment plan qualities that can be achieved over a wide range of clinical cervical cancer cases. The study demonstrated that all three sources can be used with the DMBT tandem to achieve plan qualities superior to that generated with a Con.T applicator and the ubiquitous 192 Ir source. With a practical design that do not have any moving parts unlike other designs, 24, 29, 30 compatible with the currently available HDR brachytherapy sources (Fig. 3) , and the directional dose distributions that can be easily modeled through the latest model based dose calculation algorithms (MBDCA), 48 the DMBT tandem applicator is well-suited for clinical use where image guided brachytherapy (IGBT) infrastructure is established. That is, the tungsten alloy used in the DMBT tandem design [ Figs. 1(i), 1(j) ], has been thoroughly tested for MRI compatibility at 1.5 T recently, 38 generating minimal artifacts compared to the titanium applicators, and also shown to produce acceptable MR images at 3.0 T. 49 With the use of widely available commercial metal artifact reduction algorithms, the DMBT prototype applicator also generated clinically acceptable CT images. 50 Though not published, the tandem applicator is well visible in ultrasound as well. Therefore, the proposed DMBT tandem design is compatible with all of the major medical imaging modalities used in IGBT. [42] [43] [44] thus the resulting photon interactions in the medium are dominated by multiple scattering that compensates for higher photoelectric absorptions leading to a superior depth dose curve than the other two sources [ Fig. 2(c)] , with a gradual build-up for g L (r) at A and B points and at therapeutic distances <10 cm [ Fig. 2(a) ]. With the introduction of tungsten alloy inside the DMBT tandem, the depth dose curves for all three sources diminished slightly compared with that of the open source cases [ Fig. 2c ] and resulting in varying degree of leakage radiation emitted on the back side of the applicator [ Fig. 2(d) ]. The DMBT back side transmission at 1 cm (3 cm) depth with the 192 Ir, 60 Co, and 169 Yb sources were 16.5% (29.2%), 37.5% (64.5%), and 2.44% (6.81%) respectively. These back side transmission levels demonstrate the varying degree of directional radiation beams that can be generated with the DMBT tandem, resulting in the ability to generate highly conformal dose distributions. Since the 169 Yb source generates the most directional radiation beam with DMBT (Fig. 3) , due to having the least back side transmission [ Fig. 2(d) ] while generating a similar open-sided depth dose curve to other sources [ Fig. 2(c) ], it is able to generate best treatment plans (Fig. 4) .
What we found in high correlation is that for CTV HR volume ≤30 cm 3 , the plan quality showed little dependence on the source energy while beyond this point the dependence grew stronger as the target volume became bigger and more irregular in shape. This is where the capability of an applicator to modulate the dose distribution becomes important as the 169 Yb-DMBT combination is able to produce the best plans. This also means that the use of 60 Co source with the DMBT tandem can effectively produce better quality plans than the conventional 192 Ir-T&R combination (Fig. 4) Co source when the DMBT applicator is available. Or, alternatively, if financial and/or logistics works out, it may be that the simultaneous use of all three sources can achieve the best quality plans, i.e., using the three source energies in the optimization input, assuming such an afterloader exists. Our results showed that 11/45 patient cases (24%) with 60 Co, 19/ 45 (42%) with 192 Ir, and 18/45 (40%) 169 Yb had at least one OAR in a plan that had higher D 2 cm3 than the respective reference plans. Also, to reduce complication rates, [10] [11] [12] 21 and radiation related morbidities 22 due to the dose-response effect of OARs, it is important to limit the dose levels to below the GEC-ESTRO 14-17 /ICRU-89 1 dose constraints. Therefore, the combinational use of the three sources in different but appropriate situations may be able to reduce or eliminate such occurrences. This idea of "energy modulation" 51 in addition to the "direction modulation" of dose with the DMBT tandem is not such a far-fetched idea as there was a recent introduction of a dual-source afterloader system (Flexitron TM , Elekta Brachytherapy, Veenendaal, The Netherlands). 52 Such additional degree of freedom in intensity modulation may even possibly lead to the elimination of the use of interstitial needles in some cases, as partly shown recently with the 192 Ir-DMBT combination. 36 
CONCLUSIONS
The DMBT tandem represents a promising alternative to the ubiquitous single-channel tandem design with significant improvement to the plan quality for a wide range of target volumes. Plans generated with the 169 Yb-DMBT T&R produced the best results for larger and irregularly shaped CTV HR in terms of OAR sparing while for target volumes ≤30 cm 3 all three sources generated comparable plans. Nevertheless, any of the three sources used in combination with the DMBT tandem applicator produced better quality plans than the conventional 192 Ir-T&R plans. Thus, this study suggests that the DMBT tandem applicator provides opportunity for plan quality improvement in wide ranging scenarios and clinical cases where an infrastructure is available to perform IGBT, with any medical imaging system(s).
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